Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia
Hematol Oncol Stem Cell Ther
.
2020 Dec;13(4):251-254.
doi: 10.1016/j.hemonc.2019.05.006.
Epub 2019 Jun 10.
Authors
Ibrahim N Muhsen
1
,
Ali Alahmari
2
,
Mohammed Alnahedh
3
,
Nora A Alkhudair
4
,
Hadeel Samarkandi
3
,
Riad El Fakih
5
Affiliations
1
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
2
Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
3
Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
4
Department of Clinical Pharmacy, King Saud University, Riyadh, Saudi Arabia.
5
Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Electronic address: riadfakih@hotmail.com.
PMID:
31202670
DOI:
10.1016/j.hemonc.2019.05.006
No abstract available
Keywords:
Autoimmune hemolytic anemia; Bortezomib; Immune thrombocytopenia.
Publication types
Editorial
Letter
MeSH terms
Anemia, Hemolytic, Autoimmune / drug therapy*
Bortezomib / therapeutic use*
Humans
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Substances
Bortezomib